MWNA
ARQT icon

Marshall Wace North America’s Arcutis Biotherapeutics ARQT Stock Holding History

Marshall Wace North America’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-96,954
Closed -$2.81M – 1439
2021
Q1 		$2.81M Buy
96,954
+76,293
+369% +$2.38M 0.01% 721
2020
Q4 		$581K Buy
+20,661
New +$506K ﹤0.01% 1054
2020
Q2 		– Sell
-41,315
Closed -$1.23M – 1149
2020
Q1 		$1.23M Buy
+41,315
New +$1.11M 0.01% 577

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace North America's ARQT Position: Q2 2021 in Review

Marshall Wace North America sold out of Arcutis Biotherapeutics (ARQT) in Q2 2021, closing a stake of 96,954 shares — an estimated $2.81M sold.

Marshall Wace North America first reported a position in ARQT in Q1 2020 and held it in 3 quarters. The position peaked at $2.81M in Q1 2021. 102 funds tracked by Wall St. Rank hold ARQT as of Q2 2021.

  • Marshall Wace North America reported no remaining Arcutis Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 96,954 Arcutis Biotherapeutics shares in Q2 2021, an estimated $2.81M.
  • Marshall Wace North America first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 3 quarters.
  • Marshall Wace North America's Arcutis Biotherapeutics position peaked at $2.81M in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.